よむ、つかう、まなぶ。
65歳以上の成人に対する肺炎球菌ワクチン接種に関する考え方（第7版） (22 ページ)
出典
| 公開元URL | |
| 出典情報 | 65歳以上の成人に対する肺炎球菌ワクチン接種に関する考え方（第7版）（9／30）《日本呼吸器学会》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
blind, active comparator controlled, international phase 3 trial.
Lancet Infect Dis. 2024;24:1141-50.
24.Kishino H, et al. A phase 3 randomized trial (STRIDE-9) to evaluate
the safety, tolerability, and immunogenicity of V116, a populationspecific pneumococcal conjugate vaccine, in pneumococcal vaccine-naïve
Japanese adults ≥65 years of age. Vaccine. 2025;62:127456.
25.Kobayashi M, et al. Use of 21-valent pneumococcal conjugate vaccine
among U.S. Adults: Recommendation of the advisory committee on
immunization practices–United States. MMWR Morb Mortal Wkly Rep.
2024;73:793-8.
26.Scott P, et al.
Phase 3 clinical study to evaluate the safety,
tolerability, and immunogenicity of VT-116 in pneumococcal vaccine–
experienced adults 50 years of age or older (STRIDE–6). Clin Infect
Dis 2024;79:1366-74.
27.Maeda H, et al. Serotype-distribution among adults with communityacquired pneumonia in Japan between 2019 and 2022: A multicenter
observational study. Human Vaccin Immunother. 2025;21:2518847.
28.Miyazaki T, et al. Community-acquired pneumonia incidence in adults
aged 18 years and older in Goto City, Japan. CHEST Pulmonary.
2023;1:100007.
29.Pollard AJ, et al. Maintaining protection against invasive bacteria
with protein-polysaccharide conjugate vaccines. Nat Rev Immunol.
2009;9:213
30.Azuma M, et al. Safety and immunogenicity of sequential administration
of PCV13 followed by PPSV23 in pneumococcal vaccine-naïve adults aged
≥65 years: comparison of booster effects based on intervals of 0.5 and
1.0 year. Vaccine. 2023;41:1042-9.
31. Song J-Y, et al. Safety, tolerability, and immunogenicity of V114, a
22
Lancet Infect Dis. 2024;24:1141-50.
24.Kishino H, et al. A phase 3 randomized trial (STRIDE-9) to evaluate
the safety, tolerability, and immunogenicity of V116, a populationspecific pneumococcal conjugate vaccine, in pneumococcal vaccine-naïve
Japanese adults ≥65 years of age. Vaccine. 2025;62:127456.
25.Kobayashi M, et al. Use of 21-valent pneumococcal conjugate vaccine
among U.S. Adults: Recommendation of the advisory committee on
immunization practices–United States. MMWR Morb Mortal Wkly Rep.
2024;73:793-8.
26.Scott P, et al.
Phase 3 clinical study to evaluate the safety,
tolerability, and immunogenicity of VT-116 in pneumococcal vaccine–
experienced adults 50 years of age or older (STRIDE–6). Clin Infect
Dis 2024;79:1366-74.
27.Maeda H, et al. Serotype-distribution among adults with communityacquired pneumonia in Japan between 2019 and 2022: A multicenter
observational study. Human Vaccin Immunother. 2025;21:2518847.
28.Miyazaki T, et al. Community-acquired pneumonia incidence in adults
aged 18 years and older in Goto City, Japan. CHEST Pulmonary.
2023;1:100007.
29.Pollard AJ, et al. Maintaining protection against invasive bacteria
with protein-polysaccharide conjugate vaccines. Nat Rev Immunol.
2009;9:213
30.Azuma M, et al. Safety and immunogenicity of sequential administration
of PCV13 followed by PPSV23 in pneumococcal vaccine-naïve adults aged
≥65 years: comparison of booster effects based on intervals of 0.5 and
1.0 year. Vaccine. 2023;41:1042-9.
31. Song J-Y, et al. Safety, tolerability, and immunogenicity of V114, a
22